olivacine has been researched along with Neoplasms in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Czwojdziński, E; Gąsiorowski, K; Gębarowski, T; Tylińska, B; Wiatrak, B | 1 |
Cwynar-Zając, Ł; Czyżnikowska, Ż; Dobosz, A; Gębarowski, T; Kuźniarski, A; Spychała, J; Tylińska, B | 1 |
Awada, A; Bleiberg, H; Brillanceau, MH; Calvo, F; De Valeriola, D; Dosquet, C; Eftekhary, P; Gerard, B; Giacchetti, S; Giroux, B; Lucas, C; Marty, M; Piccart, M; Poullain, MG; Soudon, J | 1 |
Berlion, M; Bourhis, J; Eschwege, F; Frascogna, V; Lucas, C; Maggiorella, L; Poullain, MG; Razy, SD | 1 |
1 trial(s) available for olivacine and Neoplasms
Article | Year |
---|---|
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.
Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2002 |
3 other study(ies) available for olivacine and Neoplasms
Article | Year |
---|---|
Lysosomal Exocytosis of Olivacine on the Way to Explain Drug Resistance in Cancer Cells.
Topics: Antineoplastic Agents; Doxorubicin; Drug Resistance; Ellipticines; Exocytosis; Lysosomes; Neoplasms | 2022 |
Evaluation of Interactions of Selected Olivacine Derivatives with DNA and Topoisomerase II.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type II; Ellipticines; Humans; Molecular Docking Simulation; Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2021 |
The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carbazoles; Cell Division; Combined Modality Therapy; Ellipticines; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mouth Mucosa; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyridines; Radiotherapy; Stomatitis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |